Navigation Links
New Blood Thinner a Promising Alternative to Warfarin
Date:11/15/2010

By Amanda Gardner
HealthDay Reporter

MONDAY, Nov. 15 (HealthDay News) -- A new blood thinner might be a viable alternative to warfarin (Coumadin), the standard for decades to treat patients with the dangerous heart rhythm disorder known as atrial fibrillation.

In research presented Monday at the American Heart Association's annual meeting in Chicago, researchers reported that rivaroxaban (Xarelto) proved to be just as good as warfarin, and possibly superior.

Rivaroxaban also reduced the risk of serious bleeding events, which is the most troubling side effect of warfarin. Dabigatran (Pradaxa), another newer-generation blood thinner, was approved by the U.S. Food and Drug Administration to treat atrial fibrillation last month.

This latest study was sponsored by Johnson & Johnson Pharmaceutical Research & Development and Bayer Healthcare, the makers of rivaroxaban.

Warfarin is the mainstay for the treatment of patients with atrial fibrillation, which affects some 2.2 million Americans. During atrial fibrillation, the heart's two small upper chambers -- called the atria -- quiver rather than beat methodically, raising the risk of blood clots and eventually a stroke.

The drug is effective in reducing the risk of stroke, but it has significant drawbacks, including the bleeding risk and difficulties with dosing and monitoring.

"In October of 2006, the FDA [U.S. Food and Drug Administration] issued a black-box warning for warfarin due to a growing appreciation of its hazards in routine clinical practice," said Dr. Elaine Hylek, who spoke at a Monday news conference on the findings, although she was not involved with the mammoth study. "The requirement for monitoring has relegated millions of people to no therapy or ineffective therapy because of lack of access to monitoring and an intense search for an alternative with more predictable dose responses."

Hylek is an associate professor of medicine at Boston University School of Medicine and reported ties with several pharmaceutical companies.

The latest trial, which scientists said was the largest of its kind, involved an international collaboration of researchers in 45 countries, 1,215 medical centers and 14,269 patients with atrial fibrillation who had already had a stroke or who had risk factors for a stroke.

"This was a very high-risk population, with multiple problems where a lot of bad stuff could happen," said study co-chair Dr. Robert M. Califf, vice chancellor for clinical research at Duke University School of Medicine and director of the Duke Translational Medicine Institute in Durham, N.C. "They're the patients we most need to protect because they're so vulnerable."

Participants, median age 73, were randomly assigned to receive rivaroxaban or warfarin.

When only patients who actually finished the trial (those who continued to take the drug) were analyzed, rivaroxaban showed a 21 percent reduced risk for stroke and non-CNS systemic embolism -- a type of blood clot.

But in the so-called "intention-to-treat" analysis, which looks at all participants, including those who stopped taking the drug, rivaroxaban did not surpass warfarin in preventing stroke or blood clots, raising questions as to how it would do in actual practice. The intention-to-treat analysis is considered the gold standard for demonstrating a drug's superiority over another drug, Califf explained.

"In a [real-world] environment where patients are going to come on and off drugs, rivaroxaban didn't meet statistical significance for superiority [against warfarin]," said Hylek. "I think it would be a more iron-clad situation [in terms of demonstrating superiority] if the intention-to-treat analysis demonstrated superiority."

Hylek added that she was not "embracing the superiority of rivaroxaban, but it's important that the new kid on the block is saying, 'I'm not inferior to you,' given that so many people can't take warfarin because of monitoring problems."

Califf said use of the new drug would be left to "clinical judgment" and emphasized the superiority of the drug in the first analysis.

There were also fewer heart attacks and fewer deaths with rivaroxaban, although these differences were not statistically significant.

More information

The American Heart Association has more on atrial fibrillation.

SOURCES: Nov. 15, 2010, news conference with Robert M. Califf, M.D., vice chancellor, clinical research, Duke University School of Medicine, and director, Duke Translational Medicine Institute, Durham, N.C.; Elaine Hylek, M.D., associate professor, medicine, Boston University School of Medicine; Nov. 15, 2010, presentation, American Heart Association annual meeting, Chicago


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Inflammatory Bowel Ups Risk for Blood Clots
2. Bowel disease link to blood clots
3. Local Blood Supply Impacted by Wednesdays Severe Snow Storm
4. PERSONALABS Offers Discounted Healthy Heart Online Blood Tests in February
5. China Cord Blood Corporation Warrant Registration Statement Declared Effective by SEC
6. NIH grants to Childrens Hospital will advance novel stem cell treatments for blood disorders
7. Bilberry Seems to Act Against Blood Sugar
8. Johns Hopkins scientists develop personalized blood tests for cancer using whole genome sequencing
9. UCR researcher identifies mechanism malaria parasite uses to spread in red blood cells
10. NHLBI, CDC launch surveillance and research program for inherited blood diseases
11. IOM report declares high blood pressure a neglected disease
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New Blood Thinner a Promising Alternative to Warfarin
(Date:10/13/2017)... ... October 13, 2017 , ... ... Software Development, has been awarded a contract by the Center for Medicare and ... aims to accelerate the enterprise use of Agile methodologies in a consistent and ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... are now treating sleep apnea using cutting-edge Oventus O2Vent technology. As ... serious sleep disorder characterized by frequent cessation in breathing. Oral appliances can offer ...
(Date:10/12/2017)... ... October 12, 2017 , ... The American College of Medical Informatics ... PhD, FACMI, during the Opening Session of AMIA’s Annual Symposium in Washington, D.C. AMIA’s ... of Morris F. Collen, a pioneer in the field of medical informatics, this prestigious ...
(Date:10/12/2017)... ... October 12, 2017 , ... HMP , a leader in ... 2017 Folio Magazine Eddie Digital Award for ‘Best B-to-B Healthcare Website.’ Winners were announced ... 2017. , The annual award competition recognizes editorial and design excellence across a range ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... (HLA), the nation's first interactive health literacy software tool, and the Cancer Patient ... aspects of cancer patient education, today announce a new strategic alliance. , ...
Breaking Medicine News(10 mins):
(Date:10/5/2017)... Ill. , Oct. 5, 2017  In ... Association of Oral and Maxillofacial Surgeons (AAOMS) released ... opioids – to be used as a first-line ... pain. Recognizing ... the AAOMS White Paper "Opioid Prescribing: Acute and ...
(Date:10/2/2017)... Mich. , Oct. 2, 2017 Diplomat ... 8th Day Software and Consulting, LLC , and ... 8th Day Software, based in Tennessee ... LLC. 8th Day expands EnvoyHealth,s service offerings for health ... development. "In an ...
(Date:10/2/2017)... 2, 2017 The Rebound mobile app is poised ... reverse the tide of prescription drug addiction. The app empowers ... intake and stepping down their dosage in a safe, controlled ... December 2017; the first 100,000 people to sign up will ... http://www.rebound-solution.com/ ...
Breaking Medicine Technology: